Esterification of fatty acids - Lipid Library - Lipid Chemistry
Lipid tasnim
-
Upload
dr-mohsin -
Category
Health & Medicine
-
view
113 -
download
0
Transcript of Lipid tasnim
![Page 1: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/1.jpg)
Lipid TransportLipoprotein Metabolism
Atherosclerosis,Dyslipoproteinaemias
Dr. Tasnim Ara JhilkyMD- Biochemistry Phase-A Student.
Sir Salimullah medical college.
![Page 2: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/2.jpg)
.
![Page 3: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/3.jpg)
.
![Page 4: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/4.jpg)
![Page 5: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/5.jpg)
![Page 6: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/6.jpg)
![Page 7: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/7.jpg)
![Page 8: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/8.jpg)
![Page 9: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/9.jpg)
![Page 10: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/10.jpg)
![Page 11: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/11.jpg)
![Page 12: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/12.jpg)
![Page 13: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/13.jpg)
![Page 14: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/14.jpg)
![Page 15: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/15.jpg)
![Page 16: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/16.jpg)
![Page 17: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/17.jpg)
![Page 18: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/18.jpg)
![Page 19: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/19.jpg)
![Page 20: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/20.jpg)
![Page 21: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/21.jpg)
![Page 22: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/22.jpg)
![Page 23: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/23.jpg)
![Page 24: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/24.jpg)
![Page 25: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/25.jpg)
![Page 26: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/26.jpg)
![Page 27: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/27.jpg)
![Page 28: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/28.jpg)
![Page 29: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/29.jpg)
![Page 30: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/30.jpg)
![Page 31: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/31.jpg)
![Page 32: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/32.jpg)
![Page 33: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/33.jpg)
![Page 34: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/34.jpg)
![Page 35: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/35.jpg)
![Page 36: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/36.jpg)
![Page 37: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/37.jpg)
![Page 38: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/38.jpg)
![Page 39: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/39.jpg)
![Page 40: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/40.jpg)
![Page 41: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/41.jpg)
![Page 42: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/42.jpg)
![Page 43: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/43.jpg)
![Page 44: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/44.jpg)
![Page 45: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/45.jpg)
![Page 46: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/46.jpg)
![Page 47: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/47.jpg)
![Page 48: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/48.jpg)
![Page 49: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/49.jpg)
![Page 50: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/50.jpg)
![Page 51: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/51.jpg)
![Page 52: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/52.jpg)
![Page 53: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/53.jpg)
![Page 54: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/54.jpg)
![Page 55: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/55.jpg)
![Page 56: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/56.jpg)
![Page 57: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/57.jpg)
![Page 58: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/58.jpg)
![Page 59: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/59.jpg)
![Page 60: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/60.jpg)
![Page 61: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/61.jpg)
![Page 62: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/62.jpg)
![Page 63: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/63.jpg)
![Page 64: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/64.jpg)
![Page 65: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/65.jpg)
![Page 66: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/66.jpg)
![Page 67: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/67.jpg)
![Page 68: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/68.jpg)
![Page 69: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/69.jpg)
![Page 70: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/70.jpg)
![Page 71: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/71.jpg)
![Page 72: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/72.jpg)
![Page 73: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/73.jpg)
![Page 74: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/74.jpg)
![Page 75: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/75.jpg)
![Page 76: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/76.jpg)
![Page 77: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/77.jpg)
AtherosclerosisAtherosclerosis is a disease of large and medium-sized muscular arteries and is
characterized by –
endothelial dysfunction,
vascular inflammation, and
the buildup of lipids, cholesterol, calcium, and cellular debris within the
intima of the vessel wall.
![Page 78: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/78.jpg)
AtherosclerosisIt is characterized by intimal lesions called atheromas (also called Atheromatous or atherosclerotic plaques), that protrude into vascular lumina.
![Page 79: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/79.jpg)
Atheromatous plaqueAn Atheromatous plaque consists of a raised lesion with a soft, yellow, grumous core of lipid (mainly cholesterol and cholesterol esters) covered by a firm, white fibrous cap.Besides obstructing blood flow, atherosclerotic plaques weaken the underlying media and can themselves rupture, causing acute thrombosis.
![Page 80: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/80.jpg)
Atheromatous plaque
Atherosclerosis or Arteriosclerosis is a slow and progressive building up of plaque, fatty substances, cholesterol, cellular waste products, calcium and fibrin in the inner lining of an artery.
![Page 81: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/81.jpg)
Risk Factors for AtherosclerosisMajor risk factors (Non Modifiable)- Increasing Age Male gender Family history Genetic abnormalities
![Page 82: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/82.jpg)
Risk Factors for AtherosclerosisLesser, Uncertain, or Nonquantitated
Risks-ObesityPhysical InactivityPostmenopausal estrogen deficiencyHigh carbohydrate intakeLipoprotein(a)Hardened (trans)unsaturated fat intakeChlamydia pneumoniae infection
![Page 83: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/83.jpg)
Risk Factors for AtherosclerosisPotentially Controllable- HyperlipidemiaHypertensionCigarette smokingDiabetesC-reactive protein
![Page 84: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/84.jpg)
Pathogenesis of AtherosclerosisThe contemporary view of atherogenesis is
expressed by the response-to-injury hypothesis.
This model views atherosclerosis as a chronic inflammatory response of the arterial wall to endothelial injury.
Lesion progression occurs through interactions of modified lipoproteins, monocyte-derived macrophages, T lymphocytes, and the normal cellular constituents of the arterial wall.
![Page 85: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/85.jpg)
Pathogenesis of Atherosclerosis1) Endothelial Injury
Initial triggering event in the development of Atherosclerotic lesions
Causes ascribed to endothelial injury in include mechanical trauma, hemodynamic forces, immunological and chemical mechanisms, metabolic agents like chronic hyperlipidemia, homocystine, circulating toxins from systemic infections, viruses, and tobacco products.
![Page 86: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/86.jpg)
Pathogenesis of Atherosclerosis2. Intimal Smooth Muscle Cell Proliferation
Endothelial injury causes adherence aggregation and platelet release reaction at the site of exposed sub endothelial connective tissue.
Proliferation of intimal smooth muscle cells is stimulated by various mitogens released from platelets adherent at the site of endothelial injury.
These mitogens include platelet derived growth factor (PDGF), fibroblast growth factor, TNF-ά.
Proliferation is also facilitated by nitric oxide and endothelin released from endothelial cells.
![Page 87: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/87.jpg)
Pathogenesis of Atherosclerosis3) Role of Blood Monocytes
Though blood monocytes do not possess receptors for normal LDL, LDL does appear in the monocyte cytoplasm to form foam cell.
Plasma LDL on entry into the intima undergoes oxidation.
Oxidized LDL formed in the intima is readily taken up by scavenger receptor on the monocyte to transform it to a lipid laden foam cell.
![Page 88: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/88.jpg)
![Page 89: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/89.jpg)
Components of Atherosclerotic plaque Atherosclerotic plaques have three
principal components: Cells, including SMCs, macrophages, and T
cells ECM, including collagen, elastic fibers, and
proteoglycans and Intracellular and extracellular lipidThese components occur in varying proportions
and configurations in different lesions.
![Page 90: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/90.jpg)
Changes in Atherosclerotic Plaque
Atherosclerotic plaques are susceptible to the following pathologic changes with clinical significance:
Rupture, ulceration, or erosionHemorrhageAtheroembolismAneurysm formation
![Page 91: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/91.jpg)
Prevention of Atherosclerotic Vascular Disease Primary prevention of atherosclerosisCessation of cigarette smoking Control of hypertensionWeight lossExercise, and lowering total and LDL blood cholesterol
levels while increasing HDL (e.g., by diet or through statins).
Statin use may also modulate the inflammatory state of the vascular wall.
Risk factor stratification and reduction should even begin in childhood.
![Page 92: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/92.jpg)
Prevention of Atherosclerotic Vascular Disease
Secondary prevention involves use of –Aspirin (anti-platelet agent), Statins, and beta blockers (to limit cardiac
demand), Surgical interventions (e.g., coronary artery
bypass surgery, carotid endarterectomy).These can successfully reduce recurrent
myocardial or cerebral events.
![Page 93: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/93.jpg)
dyslipoproteinemias
![Page 94: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/94.jpg)
Disorder of plasma lipoproteinInherited disorders.Primary hyper or hypolipoproteinemias. Due to genetic defects in lipoprotein metabolism &
transport. The secondary acquired lipoprotein disorders are
due to diabetes mellitus, nephrotic syndrome, atherosclerosis, hypothyrodism etc.
Resulting in abnormal lipoprotein patterns.
![Page 95: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/95.jpg)
hyperlipoproteinemiaElevation in one or more of the lipoprotein
fractions constitutes hyperlipoproteinemias.These disorders may be either primary or
secondary. Also called as hyperlipidemias or dyslipidemia.
![Page 96: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/96.jpg)
Frederickson's classification of hyperliporoteinemiasBased on the electrophoretic patterns of plasma
lipoproteins.In all types, the elevated lipid fraction is either
cholesterol or TAG or both.Hyerlipidemias are classified into- Hypercholesterolemia (Type IIa), Hypertriglyceridemia (Type I, IV & V) &Combined hyperlipidemia (Type IIb & Type III).
![Page 97: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/97.jpg)
The elevation of lipids in plasma leads to the deposition of cholesterol on the arterial walls, leading to atherosclerosis.The coronary & cerebral vessels are more commonly affected. Thromboembolic episodes in these vessels lead to ischemic heart disease & cerebrovascular accidents.
![Page 98: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/98.jpg)
The deposition of lipids in subcutaneous tissue leads to xanthomas. The type of xanthoma depends on the nature of lipid deposited. Eruptive xanthomata are small yellow nodules associated with deposition of triglycerides. They disappear when the lipid level falls.
![Page 99: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/99.jpg)
Type 1This is due to familial lipoprotein Iipase deficiency. It usually manifests in young age.The enzyme defect causes increase in plasma
chylomicron & triacylglycerol levels.Hepatomegaly, eruptive xanthoma & abdominal
pain are seen
![Page 100: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/100.jpg)
type11aAlso known as hyperbetalipoproteinemia.There is elevation of LDL.Caused by a defect in LDL receptors. Receptor deficiency in liver & peripheral tissues
will result in the elevation of LDL levels in plasma, leading to hypercholesterolemia.
![Page 101: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/101.jpg)
Defective binding of B-100 to the receptor.Secondary type lla hyperlipoproteinemia is observed in association with diabetes mellitus, hypothyroidism, nephrotic syndrome etc. Characterized by hypercholesterolemia.
![Page 102: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/102.jpg)
type11bBoth LDL & VLDL increase along with elevation in
plasma cholesterol & triacylglycerol. This is believed to be due to overproduction of
apo B.
![Page 103: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/103.jpg)
Type111
This is commonly known as broad beta disease.It is very rare. It is due to increased levels of LDL & IDL.Characterized by the appearance of a broad β-
band corresponding to intermediate density lipoprotein (IDL) on electrophoresis.
![Page 104: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/104.jpg)
type4This is due to overproduction of endogenous
triacylglycerols with a concomitant rise in VLDL. Cardiac manifestations are seen in the 4th decade
of life. It may be associated with diabetes mellitus,
obesity & impaired glucose tolerance.
![Page 105: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/105.jpg)
typeVChylomicrons & VLDL are elevated. This is mostly a secondary condition, due to
disorders such as obesity, diabetes and excessive alcohol consumption etc.
![Page 106: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/106.jpg)
hypolipoproteinemiaFamilial hypobetalipoproteinemia: It is an inherited disorder.Due to an impairment in the synthesis of apo B. The plasma LDL concentration in the affected
individuals is between 10 to 50% of normal values.
This disorder is harmless & the individuals have healthy & long life.
![Page 107: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/107.jpg)
abtallipoproteinemiaThis is a rare disorder due to a defect in the
synthesis of apoprotein B. It is characterized by a total absence of B-
lipoprotein (LDL) in plasma.Triacylglycerols are not found in plasma, but they
accumulate in liver & intestine. Serum cholesterol level is low
![Page 108: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/108.jpg)
Familial alpha-lipoprotein deficiency (Tangier disease)The plasma HDL particles are almost absent. Due to this, reverse transport of cholesterol is severely
affected.Accumulation of cholesteryl esters in tissues.An absence of apoprotein C ll-which activates lipoprotein
lipase-is also found. The plasma triacylglycerol levels are elevated. The affected individuals are at an increased risk for
atherosclerosis.
![Page 109: Lipid tasnim](https://reader035.fdocuments.net/reader035/viewer/2022062316/58883ec31a28ab7a298b5e75/html5/thumbnails/109.jpg)
THANK YOU .
.